Circle Pharma

Circle Pharma

Biotechnology company developing cell permeable macrocyclic peptide therapeutics using an automated chemistry synthesis.

Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macrocyclic peptide therapeutics. Computational structure-based design is combined with automated, fully synthetic chemistry. In the computational design workflow, large virtual libraries of diverse macrocycles for intrinsic cell permeability and target affinity are generated and screened. Circle Pharma’s technology allows them to target intracellular targets such as protein-protein interactions and achieve oral bioavailability. The automated chemistry synthesis is used to assess in parallel multiple design hypotheses for a given target and rapidly explore structure activity relationships. Circle Pharma is initially focused on intracellular protein-protein interactions that drive oncology pathways.

Timeline

March 17, 2020
Circle Pharma raises a $45,000,000 series B round from The Column Group.
January 17, 2018
Circle Pharma Announces Publication in Journal of Medicinal Chemistry of Results from Collaboration with Pfizer Inc.

Circle Pharma, Inc. today announced that results from its collaborative work with Pfizer Inc. to develop a potent and orally bioavailable macrocycle modulator of the chemokine receptor, CXCR7, have been published in the Journal of Medicinal Chemistry.

April 25, 2017
Circle Pharma Announces Expansion of Series A Financing and Appointment of James C. Lu to Its Board

Circle Pharma, Inc. today announced that it has completed an expansion of its Series A financing, with new investors WI Harper Group, Elements Partners, LLC, Whitesun Healthcare Ventures Limited and LifeForce Capital joining the round.

December 21, 2016
Circle Pharma raises a $4,500,000 series A round from Mission Bay Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Circle Pharma Series A round, December 2016
4,500,000
December 21, 2016
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

David C. Spellmeyer, PhD

Interim Chief Scientific Officer

David J. Earp, J.D., Ph.D.

President, CEO

Matthew P. Jacobson, Ph.D.

Co-Founder, SAB Member

R. Scott Lokey, Ph.D.

Co-Founder

Further reading

Title
Author
Link
Type
Date

Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators. - PubMed - NCBI

pubmeddev, Boehm M , et al.

Web

Peptide Therapeutics Near the Sweetest Spots

Web

March 29, 2018

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 27, 2020
BioSpace
Circle Pharma Appoints William G. Kaelin Jr. MD as Chair of Its Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.